Femasys inc. completes enrollment of femaseed pivotal trial in support of commercial launch

- topline results from femaseed ® pivotal trial expected in 1h 2024 - - commercial launch planned for early 2024 - atlanta, nov. 28, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced completion of enrollment in the local femaseed® pivotal clinical trial, designed to evaluate women undergoing femaseed cycles due to male factor infertility. femaseed, an intratubal insemination approach that delivers sperm to the fallopian tube where conception occurs is now readying for commercialization.
FEMY Ratings Summary
FEMY Quant Ranking